Page last updated: 2024-09-05

lapatinib and ldn 193189

lapatinib has been researched along with ldn 193189 in 2 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(ldn 193189)
Trials
(ldn 193189)
Recent Studies (post-2010) (ldn 193189)
1,9193051,4421130106

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)ldn 193189 (IC50)
Bone morphogenetic protein receptor type-1BHomo sapiens (human)0.0245
Platelet-derived growth factor receptor betaHomo sapiens (human)0.4856
Bone morphogenetic protein 4Homo sapiens (human)0.0049
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.4314
Bone morphogenetic protein receptor type-1AHomo sapiens (human)0.0124
Activin receptor type-1BHomo sapiens (human)0.7218
TGF-beta receptor type-1Homo sapiens (human)0.431
Serine/threonine-protein kinase receptor R3Homo sapiens (human)0.0147
TGF-beta receptor type-2Homo sapiens (human)0.1482
Dual specificity protein kinase CLK2Homo sapiens (human)0.4856
5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)0.4856
Activin receptor type-1Homo sapiens (human)0.2081
Bone morphogenetic protein receptor type-2Homo sapiens (human)3.845
5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)0.6129

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB1

Other Studies

2 other study(ies) available for lapatinib and ldn 193189

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Journal of medicinal chemistry, 2014, Oct-09, Volume: 57, Issue:19

    Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship

2014